Supernus Pharmaceuticals
9715 Key West Avenue
Rockville
Maryland
20850
United States
Tel: 301-838-2501
Website: http://www.supernuspharma.com/
236 articles about Supernus Pharmaceuticals
-
Supernus to Participate in Two Upcoming March 2023 Investor Conferences
3/8/2023
Supernus Pharmaceuticals, Inc. announced that the Supernus Pharmaceuticals management team will participate in the following March investor conferences:
-
Supernus to Present at the Cowen 43rd Annual Health Care Conference
3/1/2023
Supernus Pharmaceuticals, Inc. announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat, as well as host investor meetings, at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 9:50 a.m. ET.
-
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
2/28/2023
Supernus Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year of 2022 and associated Company developments.
-
Supernus Enters Into $150 Million Credit Facility
2/14/2023
Supernus Pharmaceuticals, Inc. announced it entered into a credit line agreement with UBS Bank USA providing the Company an uncommitted demand secured line of credit of up to $150 million, which can be drawn at any time.
-
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
2/9/2023
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2022 after the market closes on Tuesday, February 28, 2023.
-
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
11/22/2022
Supernus Pharmaceuticals, Inc. announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat, as well as host investor meetings, at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022, at 10:30 a.m. ET.
-
Supernus to Present at Two November 2022 Healthcare Conferences
11/8/2022
Supernus Pharmaceuticals, Inc. announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will present a Company overview and update, as well as host investor meetings, at the following November conferences.
-
Supernus Announces Third Quarter 2022 Financial Results
11/8/2022
Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced financial results for the third quarter of 2022, and associated Company developments.
-
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
10/25/2022
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) today announced that the Company expects to report financial and business results for the third quarter of 2022 after the market closes on Tuesday, November 8, 2022.
-
Supernus Provides Regulatory Update on SPN-830
10/10/2022
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the SPN-830 New Drug Application (NDA).
-
Supernus to Present at the 2022 Wells Fargo Healthcare Conference
8/31/2022
Supernus Pharmaceuticals, Inc. announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 8:35 a.m. ET.
-
Supernus Announces Second Quarter 2022 Financial Results
8/4/2022
Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced financial results for the second quarter of 2022, and associated Company developments.
-
Supernus to Participate in the Jefferies Healthcare Conference
6/2/2022
Supernus Pharmaceuticals, Inc. announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 10:30 a.m. ET.
-
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
5/2/2022
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2022 after the market closes on Monday, May 9, 2022.
-
Notably, Qelbree is the first novel FDA approval of a novel non-stimulant treatment for ADHD in adults in 20 years.
-
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
4/30/2022
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), announced today that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older.
-
Bristol Myers Squibb will hear from the FDA on April 28 about Mavacamten, while Supernus, Axsome, Coherus, Hutchmed and Incyte also await the fate of their respective drug candidates.
-
Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
4/13/2022
Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, filed its Annual Report on Form 10-K and reported final audited financial results for the fourth quarter and full year ended December 31, 2021.
-
Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance
4/4/2022
Supernus Pharmaceuticals, Inc. today announced that it expected to file its Annual Report on Form 10-K for the fiscal ended December 31, 2021 (the “Annual Report”) in the near term.
-
Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance
3/17/2022
Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, filed a notification of Late Filing on Form 12b-25 on March 1, 2022, indicating that the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 would be delayed.